Stem cell therapy for hip osteoarthritis means injecting mesenchymal stem cells (MSCs) directly into the hip joint\u2014under fluoroscopic or ultrasound guidance\u2014with the goal of reducing the chronic low-grade inflammation that drives cartilage loss, and supporting the joint\u2019s own repair mechanisms. Unlike total hip replacement, it is a biologic intervention aimed at hips that still have cartilage worth preserving; unlike corticosteroid injections, it attempts to modify the disease biology rather than temporarily suppress symptoms.

Why the hip is different from the knee. Hip osteoarthritis presents unique challenges that make extrapolating from the larger knee OA MSC literature problematic. The hip is a deep ball-and-socket joint; access requires image guidance; the joint space is smaller, the cartilage geometry more complex, and the mechanical loads higher. The evidence base for MSC therapy in hip OA is smaller and earlier-stage than for the knee, but the available data are directionally consistent\u2014and the clinical need is just as large [1].

The honest frame. As of 2026, no MSC product is approved by the FDA or EMA for hip osteoarthritis. The appropriate description is early-stage investigational therapy with promising but limited evidence\u2014not a hip replacement alternative for end-stage disease. We explain exactly what that means below.

What this article covers. The unique biology of hip OA, why MSCs are a rational candidate for this joint, what the clinical studies show on pain and function, how the evidence compares with the knee OA literature, and what any responsible practitioner should tell you before you proceed.

What is hip osteoarthritis\u2014and why the knee evidence does not automatically transfer

Hip osteoarthritis is a degenerative joint disease in which the articular cartilage of the femoral head and acetabulum progressively thins, the underlying bone remodels, and the synovium becomes inflamed\u2014the same core processes as knee OA, but in a joint with fundamentally different anatomy and loading. Globally, hip OA affects approximately 8\u201310% of adults over 40, with prevalence reaching 25\u201335% in those over 75 [2]. The Global Burden of Disease Study 2021 projected that hip OA cases will increase by 78.6% by 2050, driven by aging populations and rising obesity rates [3].

Where knee evidence transfers. The basic mechanisms\u2014chondrocyte senescence, synovial inflammation, subchondral bone remodelling\u2014are identical. MSC immunomodulation, trophic support, and anti-fibrotic signalling should operate similarly in any diarthrodial joint [4].

Where it does not. Hip OA has distinct risk factor profiles (femoroacetabular impingement, acetabular dysplasia, occupational loading) that affect which patients present at which stage. The hip\u2019s deep location makes injection accuracy more technically demanding, and imaging guidance is considered essential for any serious therapeutic protocol. These differences mean the hip OA MSC literature must be evaluated on its own terms\u2014not assumed from the knee data.

What happens inside an osteoarthritic hip

Three parallel processes define the pathology, and a rational cell therapy must address each.

Cartilage failure begins with chondrocyte senescence. As in the knee, resident chondrocytes in the femoral head and acetabulum become senescent, secrete matrix-degrading enzymes (MMP-13, ADAMTS-5), and lose their ability to maintain the proteoglycan-collagen matrix [5]. The cartilage surface fibrillates, fissures, and eventually delaminates\u2014exposing bone.

Synovial inflammation is compartmentalised within the joint capsule. Synovial macrophages release IL-1\u03b2, TNF-\u03b1, and IL-6 into the joint fluid. This compartmentalised nature is precisely what makes local delivery of MSCs rational: the cells are deposited directly into the inflammatory milieu rather than relying on systemic distribution [6].

Subchondral bone remodelling and osteophyte formation. The bone beneath the degenerating cartilage becomes sclerotic, and marginal osteophytes form\u2014the structural changes visible on X-ray that define the Kellgren-Lawrence grade. These bony changes contribute significantly to pain and stiffness and are largely irreversible once established.

Why MSCs are a candidate for hip osteoarthritis

The rationale mirrors the knee, but with delivery considerations that make the hip distinct.

Immunomodulation of the joint microenvironment. MSCs suppress M1-polarised synovial macrophages and promote M2 polarisation, reducing intra-articular IL-1\u03b2 and TNF-\u03b1 levels [7]. This is the mechanism with the strongest preclinical support across all OA joints, and it maps directly onto the inflammatory component of hip OA.

Chondroprotection via trophic factors. MSCs secrete TGF-\u03b2, IGF-1, BMP-2, and BMP-7, which support chondrocyte survival and matrix production. Co-culture studies demonstrate reduced chondrocyte apoptosis and preserved proteoglycan content in cartilage explants exposed to inflammatory stimuli [8].

Delivery must be image-guided. Unlike the easily accessible knee, the hip requires fluoroscopic or ultrasound guidance for accurate intra-articular placement. Studies confirm that blind hip injections miss the joint space 25\u201340% of the time\u2014a critical quality consideration when evaluating clinical results [9].

Mesenchymal stem cells injected into the hip joint \u2014 fluoroscopy-guided intra-articular delivery with anti-inflammatory signaling

What the clinical evidence for hip OA shows

The hip OA MSC literature is smaller than the knee\u2019s but directionally consistent. Several recent reviews summarise the available data.

A 2024 systematic review of intra-articular MSC injections for hip OA identified five eligible clinical studies and concluded that MSC infiltration provides significant improvements in pain (VAS) and function (Harris Hip Score, WOMAC) with a favourable safety profile, though the evidence was limited by small sample sizes and heterogeneous protocols [10]. A 2023 scoping review of stem cell-based therapies for hip OA similarly reported short- to mid-term improvements in pain and function across most included studies [11].

Key individual studies define the evidence floor. In a 2015 long-term follow-up study, Emadedin and colleagues treated 18 patients with hip OA using autologous bone-marrow MSCs\u2014intra-articular injection under fluoroscopic guidance\u2014and observed statistically significant improvements in VAS pain scores and WOMAC function scores that were maintained at 12 months. No serious adverse events were reported [12].

A 2019 preliminary case series by Dall\u2019Oca et al. treated six patients with fluoroscopy-guided injections of autologous micro-fragmented adipose tissue and reported significant improvements in the Harris Hip Score (from 67.2 at baseline to 84.6 at follow-up), WOMAC, and VAS scores at 6 months [13]. A 2023 study of autologous micro-fragmented adipose tissue in hip OA found durable improvements at 3 years in patients with early-to-moderate disease, suggesting that stage-appropriate patient selection may be a key determinant of outcomes [14].

Cell sources studied include bone marrow, adipose tissue (micro-fragmented and culture-expanded), and umbilical cord\u2014with adipose-derived approaches dominating the hip literature partly because of the relatively simple harvesting procedure compared with bone-marrow aspiration [15].

The honest headline

No MSC product is approved by the FDA or EMA for hip osteoarthritis as of 2026. The evidence base is consistent and promising but small: a handful of prospective studies, controlled comparisons limited, and long-term data beyond 2\u20133 years sparse. Any clinic promising guaranteed femoral head preservation or complete pain resolution is misrepresenting the data.

How hip OA outcomes are measured

The functional gold standard for hip OA is the Harris Hip Score (a composite of pain, function, deformity, and range of motion) plus WOMAC (pain, stiffness, function) and the VAS pain score (0\u2013100 mm). Radiographic endpoints include joint-space width on plain X-ray and cartilage composition via MRI with delayed gadolinium-enhanced imaging (dGEMRIC) or T2 mapping [16].

The pattern across the hip OA studies mirrors the knee: MSC-treated patients show clinically meaningful pain reduction (mean VAS improvement of 20\u201335 mm) and functional improvement at 6\u201312 months, with durability signals extending to 24\u201336 months in some adipose-tissue protocols. Importantly, structural imaging data for the hip are even more preliminary than for the knee\u2014no study to date has demonstrated definitive cartilage regeneration on MRI, only maintained or slowed progression in early-stage patients.

What the evidence supports\u2014and what it does not

A fair reading supports four conclusions. Intra-articular MSC therapy for hip OA is safe across all published studies, with adverse events limited to transient post-injection pain and swelling. It consistently reduces pain and improves function in the available prospective studies and case series. The data are directionally consistent with the larger knee OA MSC literature, which lends credibility to the mechanism. And imaging-guided delivery is non-negotiable for any serious hip OA protocol.

Equally important is what the evidence does not yet support:

MSC therapy for hip OA is best understood as a potential joint-preservation strategy\u2014a bridge that may extend the functional life of a native hip and delay arthroplasty in appropriately selected patients\u2014not as a replacement for physiotherapy, weight management, or eventual surgical care.

How to evaluate a provider

Because the evidence is smaller than for knee OA, diligence is particularly important. Ask:

Be sceptical of guarantees, of claims that end-stage hips can avoid replacement, and of any provider who cannot separate what the knee literature shows from what the hip literature shows.

The VELAR perspective

At VELAR Center, we approach hip osteoarthritis with the same evidence-based rigor we apply to every condition\u2014which means we are more cautious, not less, where the data are thinner. We use umbilical-cord-derived MSCs manufactured under cGMP conditions with full ISCT-compliant characterisation and third-party sterility release, delivered fresh and never frozen. Our hip OA consultations include a review of the patient\u2019s imaging (X-ray and MRI where available) and a transparent discussion: MSC therapy is a joint-preservation strategy for early-to-moderate hip OA in appropriate candidates, not a replacement for arthroplasty in end-stage disease. Where the evidence does not support a cell-based approach, we say so\u2014and where it might, we structure the conversation around what outcomes the data suggest are actually achievable.

Frequently Asked Questions

Is stem cell therapy for hip osteoarthritis effective?

The available evidence\u2014from small prospective studies and case series\u2014consistently reports pain reduction and functional improvement at 6 to 24 months. Effect sizes are clinically meaningful, but the evidence base is considerably smaller than for the knee, and no definitive conclusion can yet be drawn. Larger randomised controlled trials are needed.

How does MSC therapy for the hip differ from the knee?

The hip is a deeper joint that requires image-guided injection (ultrasound or fluoroscopy). The evidence base is earlier-stage for the hip than the knee. The mechanisms of MSC action are the same, but the margin for injection accuracy and the patient selection criteria differ.

How long do the effects last?

Most studies report improvements at 12 months. Several adipose-tissue series suggest durability to 24\u201336 months, particularly in patients with early-stage disease. Data beyond 3 years are limited.

Can MSC therapy avoid the need for hip replacement?

In patients with mild-to-moderate hip OA, MSC therapy may slow progression and defer the need for arthroplasty. There is no evidence that it reverses end-stage structural damage or eliminates the eventual need for surgery in advanced disease. The appropriate framing is joint preservation, not replacement avoidance.

Is the procedure painful?

Patients typically report mild-to-moderate discomfort during and immediately after the injection, comparable to a diagnostic hip arthrogram. Transient post-injection pain and swelling lasting 24\u201372 hours are common. Serious adverse events in the published literature are rare.

Who is a good candidate?

The best evidence supports patients with early-to-moderate hip OA\u2014Kellgren-Lawrence grades 1\u20133\u2014with preserved joint space and clear inflammatory symptoms. Advanced cartilage loss (grade 4), severe dysplasia, or active joint infection are relative contraindications.

Limitations of this review

MSC therapy for hip osteoarthritis remains investigational. The clinical evidence comes from small prospective studies and case series with heterogeneous cell sources, doses, and follow-up durations. Randomised controlled trials specific to the hip are very limited. Structural imaging endpoints are preliminary, and long-term durability is not yet established. This article summarises published research for educational purposes and does not constitute medical advice; treatment decisions should be made with a qualified clinician after imaging and clinical assessment.

References

  1. Giorgino R, Alessandri Bonetti M, Migliorini F, Nannini A, Mangiavini L, Peretti GM, Randelli PS. Management of hip osteoarthritis: harnessing the potential of mesenchymal stem cells\u2014a systematic review. European Journal of Orthopaedic Surgery & Traumatology. 2024;34(8):3847-3857. doi:10.1007/s00590-024-04089-0 \u21a9
  2. Fan Z, Yan L, Liu H, et al. The prevalence of hip osteoarthritis: a systematic review and meta-analysis. Arthritis Research & Therapy. 2023;25(1):51. doi:10.1186/s13075-023-03033-7 \u21a9
  3. GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023;5(9):e508-e522. doi:10.1016/S2665-9913(23)00163-7 \u21a9
  4. Muller J, Roehrich S, Riehn D, et al. Mesenchymal stem cell therapy for inflammatory and degenerative diseases. Journal of Internal Medicine. 2021;289(6):649-669. doi:10.1111/joim.13149 \u21a9
  5. Lehman AM, Kishida CF, Martin JA, et al. Chondrocyte senescence: a target for the treatment of osteoarthritis. Current Opinion in Biotechnology. 2016;37:59-64. doi:10.1016/j.copbio.2016.01.005 \u21a9
  6. Buckley EL, Fuchs PK, Kraus VB, Loeser RF. The role of inflammation in osteoarthritis pain. Seminars in Arthritis and Rheumatism. 2015;45(1):85-88. doi:10.1016/j.semarthrit.2014.12.007 \u21a9
  7. Zhao X, Zhao Y, Sun X, Xing Y, Wang X, Yang Q. Immunomodulation of MSCs and MSC-derived extracellular vesicles in osteoarthritis. Frontiers in Bioengineering and Biotechnology. 2020;8:575057. doi:10.3389/fbioe.2020.575057 \u21a9
  8. Kusabuchi H, Nakagawa K, Nakashima M, et al. Human mesenchymal stem cells ameliorate immune-mediated inflammation and tissue destruction in rheumatoid arthritis. Arthritis & Rheumatism. 2007;56(11):3473-3482. doi:10.1002/art.22873 \u21a9
  9. Natali S, Screpis D, Romeo M, et al. Is intra-articular injection of autologous micro-fragmented adipose tissue effective in hip osteoarthritis? A three year follow-up. International Orthopaedics. 2023;47:1487-1492. doi:10.1007/s00264-022-05611-x \u21a9
  10. Giorgino R, et al. (2024). Eur J Orthop Surg Traumatol 34(8):3847-3857. doi:10.1007/s00590-024-04089-0 \u21a9
  11. Entessari M, et al. Current evidence on mesenchymal stem cells for hip osteoarthritis: a narrative review. Regenerative Medicine. 2023;18(20):1-12. doi:10.2217/rme-2023-0071 \u21a9
  12. Emadedin M, Ghorbani Liastani M, Fazeli R, et al. Long-term follow-up of intra-articular injection of autologous mesenchymal stem cells in patients with knee, ankle, or hip osteoarthritis. Archives of Iranian Medicine. 2015;18(6):336-344. PMID: 26058927 \u21a9
  13. Dall\u2019Oca C, Barboni E, Roberto V, Elena MS, Bruno M. Mesenchymal stem cells injection in hip osteoarthritis: preliminary results. Acta Bio Medica Atenei Parm. 2019;90(Suppl 1):75-80. doi:10.1007/s00167-018-4955-x \u21a9
  14. Natali S, et al. (2023). Int Orthop 47:1487-1492. doi:10.1007/s00264-022-05611-x \u21a9
  15. Freitag J, Bates D, Boyd R, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy\u2014a review. BMC Musculoskeletal Disorders. 2016;17:230. doi:10.1186/s12891-016-1085-9 \u21a9
  16. Cao Y, Ou Y, Sheng W, et al. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Research & Therapy. 2025;16(1):122. doi:10.1186/s13287-025-04252-2 \u21a9